Mayo and Gentag Partner to Develop Wearable Biosensors for Treating Diabetes

Mayo Clinic and Gentag, Inc. have teamed up to develop next-generation, wearable biosensors designed to fight diabetes and obesity.

The companies have reached a joint intellectual property (IP) agreement to develop the first-of-its-kind, wearable patch sensors, which are wireless and the size of a small bandage. The sensors are designed to be painless and disposable. In the bandage is a sensor that communicates through a closed-loop diabetes management system which is compatible with cell phones. The system will allow researchers to monitor movement and develop treatments for obesity, diabetes and related conditions.

“We are hoping that this technology will be game-changer. These patch biosensors may help us reduce global obesity and diabetes,” said James Levine, MD, PhD, a Mayo Clinic endocrinologist and obesity researcher. “They are accurate, inexpensive, and can be integrated into the care people receive.”

Gentag signed a patent pooling agreement with Mayo Clinic for the management of IP related to wearable patch sensor and wireless communication technologies. Under the deal, certain patent rights and technologies of both organizations will be combined and commercialized. Mayo and Gentag will collaborate with third parties under license to bring Mayo’s expertise in medicine and clinical practices to the public by development of the next generation of wearable skin patch technologies from Gentag in the areas of diabetes and obesity management. Under the agreement, more than 50 issued patents and technologies are being offered for licensing.

“We are thrilled to be cooperating with the Mayo Clinic on these amazing new wireless technologies,” said John Peeters, PhD, the CEO of Gentag. “We look forward to working with the new medical device community to get this technology into the marketplace.”

In addition, Mayo’s Micro-Miniature Transceiver chip will be combined with Gentag’s radar-responsive tag technology and integrated under license to create a new type of communication chip that will combine Near Field Communication (NFC), Body Area Networks (BAN), as well as long-range wireless communication and geolocation.

Source: Mayo Clinic

Last updated: 3/4/15; 2:30pm EST


Check Also

Natera Announces SMART Study Data for Aneuploidy and 22q Unblinded

SAN CARLOS, Calif., Sept. 2, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and …

Leave a Reply

Your email address will not be published. Required fields are marked *